{"article_title": "Morning Read: Novo Nordisk acquires 2 U.S. biotechs targeting diabetes, insurers get greenlight on double digit rate hikes", "article_keywords": ["novo", "novel", "targeting", "nordisk", "cancer", "read", "double", "drug", "morning", "hikes", "rate", "health", "greenlight", "llc", "policy", "insurers", "mb2", "wall", "care"], "article_url": "http://medcitynews.com/2015/08/novo-nordisk-acquires-biotechs/", "article_text": "TOP STORIES\n\nNovo Nordisk is acquiring Indiana-based Calibrium LLC and MB2 LLC, both of which are relatively fresh on the scene and working on drug targets for diabetes and metabolic diseases. The financial details are still being kept under wraps.\n\nCalibrium is focused on novel peptides and MB2 LLC on first-in-class, mixed agonist drugs. \u201cI\u2019m optimistic that together we can create novel, transformative therapies in the fight against the global epidemic of diabetes and obesity,\u201d said Richard DiMarchi, chief scientific officer and co-founder of both Calibrium and MB2, commenting on the deal. \u2014 PharmaTimes\n\nSome insurers have received the double digit rate increases they were seeking after state commissioners agreed that the increases were needed to cover higher-than-expected claims from sick people who signed up for individual policies in the first two years of the Affordable Care Act. The rate hikes will go into effect in time for the open enrollment period, which starts November 1. Blue Cross Blue Shield of Tennessee marks the highest rate increase to date at 36.3 percent. The state has had some of the lowest premiums in the country in the first couple of years of ACA\u2019s rollout. \u2014 The Wall Street Journal\n\nLIFE SCIENCES\n\nIt looks like Lilly\u2019s cancer drug necitumumab, developed for the treatment of a form of advanced lung cancer, is taking center stage in the continued debate of pricing of cancer drugs. \u2014 The Wall Street Journal\n\nThe US Food and Drug Administration (FDA) released its long-awaited guidance establishing a naming convention for biosimilars to distinguish them from branded versions of thee products. \u2014 RAPS\n\nThe FDA has also approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL) cholesterol under control with current treatment options. \u2014 Bio Century\n\nPAYERS-PROVIDERS\n\nA judge in Arizona ruled that a hospital assessment that pays for the expansion of the state\u2019s Medicaid program is constitutional, preserving health care for some 350,000 Arizonans. \u2014 Arizona Daily Star\n\nTECH\n\nThe latest healthcare accelerator to come into being is a collaboration between Johnson & Johnson Innovation and PCH called Hardware for Health. Stacy Feld, Senior Director of Consumer Scientific Innovation at JJI, told MobiHealthNews:\n\n\u201cThere are new devices, new software algorithms, advanced sensor technologies, and novel imaging innovations. And as these new hardware solutions are converging on the consumer health ecosystem, that\u2019s enabling new solutions for consumers to engage in self-care and general health and wellness.\u201d \u2014 MobiHealth News\n\nPOLITICS\n\nSpeaker John Boehner has hired one of the House Energy and Commerce Committee\u2019s top aides to advise him on health care policy. Paul Edattel, who has worked on Rep. Fred Upton\u2019s (R-Mich.) panel since 2011, will begin as assistant to the speaker for policy, in charge of the Ohio Republican\u2019s health care policy.\n\n\u2014 Politico\n\nA LITTLE BIT EXTRA\n\nSome people actually have a condition called \u201caphantasia,\u201d which doesn\u2019t allow them to picture things visually in their mind.\n\nIt\u2019s thought that as many as one in fifty people might have aphantasia. Some report that it makes them feel \u201calone\u201d or \u201cisolated,\u201d knowing that they can\u2019t see things that most people can, and that they feel distressed they can\u2019t picture friends or deceased relatives. But others have learnt to live with it, and simply think that they experience life in a different way \u2014 IFLScience\n\nPhoto: Flickr user Siebuhr", "article_metadata": {"description": "Novo Nordisk has acquired Indiana-based Calibrium LLC and MB2 LLC, which are developing drugs for diabetes and metabolic diseases, some health insurers are dramatically increasing rates.", "generator": "WordPress 4.5.2", "og": {"site_name": "MedCity News", "description": "Novo Nordisk has acquired Indiana-based Calibrium LLC and MB2 LLC, which are developing drugs for diabetes and metabolic diseases, some health insurers are dramatically increasing rates.", "title": "Morning Read: Novo Nordisk acquires 2 U.S. biotechs targeting diabetes, insurers get greenlight on double digit rate hikes", "locale": "en_US", "image": "http://medcitynews.com/wp-content/uploads/novo_flickr_siebuhr.jpg", "updated_time": "2015-10-02T11:54:14-04:00", "url": "http://medcitynews.com/2015/08/novo-nordisk-acquires-biotechs/", "type": "article"}, "twitter": {"image": "http://medcitynews.com/wp-content/uploads/novo_flickr_siebuhr.jpg", "description": "Novo Nordisk has acquired Indiana-based Calibrium LLC and MB2 LLC, which are developing drugs for diabetes and metabolic diseases, some health insurers are dramatically increasing rates.", "card": "summary", "title": "Morning Read: Novo Nordisk acquires 2 U.S. biotechs targeting diabetes, insurers get greenlight on double digit rate hikes - MedCity News"}, "robots": "noodp", "fb": {"app_id": 148725768475669}, "google-site-verification": "xudQg7nxVR9ifmMTY4Tf-0wVtX9b6rWLQd0utCweGOc", "keywords": "weight loss, obesity, overweight,diabetes,massachusetts,medical devices,obesity,startups,healthcare innovation, medcity news,medcity news,san francisco, startups, life sciences,accelerator,rock health,startup advice,startup funding,patient monitoring system, motion sensors ,dc,healthcare it,washington,foodborne pathogens, diagnostics company, diagnostic platforms,minimally invasive surgery, laser surgery,cambridge,dealflow,hospitals,wellpoint, healthways, health and wellness, employee wellness programs,investing,wellness,medtronic, shanghai innovation center, china, r&d,china,mdt,minneapolis,minnesota,publics,twin cities,ulcerative colitis, abbott labs, humira,abbott labs,doctors,pharmaceuticals,skin disorders, pharmaceuticals, md anderson cancer center,cancer,texas,renal denervation, st. jude medical,st. jude medical,stj,emr, ehr, electronic health records, electronic medical records, certified emr,certified emr,ehr,electronic health records,electronic medical records,advanced cellular technology,amyotrophic lateral sclerosis,embryonic stem cells,geron corporation,lou gehrig\\'s disease,macular degeneration,regenerative medicine,spinal cord damage,value-based healthcare system, obamacare, fee-for-service model,california,cleveland,health insurance,insurance,ohio,pennsylvania,politics,cancer treatment options library, aetna, aet, healthcare it,aet,aetna,health it,phi,philadelphia,Calibrium, Diabetes, Indiana, MB2, morning read, Novo Nordisk, , MedCity News", "article": {"section": "Daily", "tag": "Novo Nordisk", "published_time": "2015-08-28T07:55:39-04:00", "modified_time": "2015-10-02T11:54:14-04:00"}, "viewport": "width=device-width,initial-scale=1.0,width=device-width,user-scalable=no,minimum-scale=1.0,maximum-scale=1.0"}, "article_summary": "Calibrium is focused on novel peptides and MB2 LLC on first-in-class, mixed agonist drugs.\nTOP STORIESNovo Nordisk is acquiring Indiana-based Calibrium LLC and MB2 LLC, both of which are relatively fresh on the scene and working on drug targets for diabetes and metabolic diseases.\nPaul Edattel, who has worked on Rep. Fred Upton\u2019s (R-Mich.) panel since 2011, will begin as assistant to the speaker for policy, in charge of the Ohio Republican\u2019s health care policy.\n\u2014 Bio CenturyPAYERS-PROVIDERSA judge in Arizona ruled that a hospital assessment that pays for the expansion of the state\u2019s Medicaid program is constitutional, preserving health care for some 350,000 Arizonans.\nThe rate hikes will go into effect in time for the open enrollment period, which starts November 1."}